Table 4.

Association of AR mRNA expression and survival in NMIBC patients stratified by KRT5/KRT20 mRNA expression, sex, age, and instillation therapy.

Marker	Substratification Parameter	Survival	High (n)	Low (n)	Survival in Months	p-Value
AR	KRT5 low	RFS	20	18	112 vs. 49	0.003
	KRT5 high	RFS	37	10	71 vs. 89	n.s.
	KRT20 low	RFS	31	17	89 vs. 50	0.014
	KRT20 high	RFS	26	21	80 vs. 63	n.s.
	Age ≤ 71	RFS	31	17	108 vs. 58	0.021
	Age > 71	RFS	26	11	67 vs. 59	n.s.
	Male	RFS	43	28	90 vs. 61	n.s.
	Female	RFS	14	10	85 vs. 57	n.s.
	Instillation yes	RFS	24	22	78 vs. 52	n.s.
	Instillation no	RFS	33	16	91 vs. 66	n.s.
AR	KRT5 low	CSS	15	33	142 vs. 104	(0.057)
	KRT5 high	CSS	32	15	133 vs. 133	n.s.
	KRT20 low	CSS	24	24	140 vs. 108	(0.053)
	KRT20 high	CSS	23	24	155 vs. 132	n.s.
	Age ≤ 71	CSS	29	19	169 vs. 133	0.014
	Age > 71	CSS	18	29	112 vs. 102	n.s.
	Male	CSS	35	36	159 vs. 127	0.044
	Female	CSS	12	12	124 vs. 98	n.s.
	Instillation yes	CSS	19	27	158 vs. 115	0.043
	Instillation no	CSS	28	21	134 vs. 121	n.s.
AR	KRT5 low	OS	23	25	105 vs. 76	n.s.
	KRT5 high	OS	37	10	113 vs. 98	n.s.
	KRT20 low	OS	33	15	117 vs. 89	n.s.
	KRT20 high	OS	27	20	118 vs. 81	0.041
	Age ≤71	OS	34	14	140 vs. 82	0.007
	Age > 71	OS	26	21	87 vs. 76	n.s.
	Male	OS	45	26	116 vs. 88	n.s.
	Female	OS	15	9	113 vs. 64	0.011
	Instillation yes	OS	27	19	134 vs. 88	0.044
	Instillation no	OS	33	16	101 vs. 73	0.031

Significant values (p < 0.05) are marked in bold. Values p ≥ 0.05 to 0.1 are in parentheses. Values p > 0.1 are marked as not significant (n.s.).